Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Table 3 Farnesyl-transferase inhibitor in clinical trials

inhibitors	Other agents	Disease	Dosage	Clinical trails	No Pts	Response	Reference
Tipifarnib	Bortezomib 1.0 mg/m²	Elderly or relapsed AML	300-600 mg bid, ×21d	Phase II	80	CR: 11%	[30]
Tipifarnib	+/- etoposide	Elderly untreated AML		Phase II	107	Safe	[31]

ISSN: 1756-8722